Why the study?
There are no reliable molecular targets for early diagnosis and effective treatment in the clinical management of diabetic kidney disease.
Population
Public transcriptomic datasets of alloxan-induced and streptozotocin-induced DKD models, validated in db/db DKD mice
Comparison
DKD models vs control animals
Design
Integrative bioinformatic analysis and preclinical validation study
Authors
Loading...
Hypothesis-generating for these genes in DKD; human validation needed before any clinical consideration.
Hmgcs2, Angptl4, and Slco1a1 were identified as key differentially expressed genes consistently altered across multiple diabetic kidney disease models, highlighting them as potential biomarkers or therapeutic targets.
Xu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: